Cmp Dev Llc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CMP DEV LLC, and what generic alternatives to CMP DEV LLC drugs are available?
CMP DEV LLC has six approved drugs.
There are twenty-three US patents protecting CMP DEV LLC drugs.
There are sixteen patent family members on CMP DEV LLC drugs in nine countries and fifty-two supplementary protection certificates in eleven countries.
Summary for Cmp Dev Llc
| International Patents: | 16 |
| US Patents: | 23 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for Cmp Dev Llc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | CAROSPIR | spironolactone | SUSPENSION;ORAL | 209478-001 | Aug 4, 2017 | AB | RX | Yes | Yes | 10,624,906 | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Cmp Dev Llc | LIQREV | sildenafil citrate | SUSPENSION;ORAL | 214952-001 | Apr 28, 2023 | DISCN | Yes | No | 11,464,778 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,723,866 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | 11,975,006 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | 11,253,474 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | 11,382,917 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cmp Dev Llc Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 3086881 | ⤷ Sign Up |
| Morocco | 50320 | ⤷ Sign Up |
| European Patent Office | 3468606 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2020081118 | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2017212409 | ⤷ Sign Up |
| Australia | 2018397436 | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cmp Dev Llc Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1441735 | 2008/010 | Ireland | ⤷ Sign Up | PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220; |
| 0720599 | CR 2014 00050 | Denmark | ⤷ Sign Up | PRODUCT NAME: EZETIMIBE AND ATORVASTATIN OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING ATORVASTATIN AS ATORVASTATIN CALCIUM TRIHYDRATE; REG. NO/DATE: DE/H/3895-3898/001-004/DC 20140910 |
| 0740668 | PA2003001,C0740668 | Lithuania | ⤷ Sign Up | PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328 |
| 0463756 | 99C0007 | Belgium | ⤷ Sign Up | PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622 |
| 3141251 | 301099 | Netherlands | ⤷ Sign Up | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
| 1718641 | 2012/008 | Ireland | ⤷ Sign Up | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
